I3392
Anti-Interleukin-1α antibody produced in goat
IgG fraction of antiserum, lyophilized powder
Sinónimos:
Anti-IL-1α
Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
About This Item
Productos recomendados
origen biológico
goat
Nivel de calidad
conjugado
unconjugated
forma del anticuerpo
IgG fraction of antiserum
tipo de anticuerpo
primary antibodies
clon
polyclonal
Formulario
lyophilized powder
reactividad de especies
mouse
técnicas
indirect ELISA: suitable
neutralization: suitable
western blot: suitable
Nº de acceso UniProt
temp. de almacenamiento
−20°C
Información sobre el gen
mouse ... Il1a(16175)
¿Está buscando productos similares? Visita Guía de comparación de productos
Categorías relacionadas
Descripción general
Interleukins are proinflammatory cytokines produced on cell injury or trauma. There are two closely related types of interleukins produced by the cell, IL-1α and IL-1β that are produced by the activation of NF-κ B transcription factor in response to bacterial infection or LPS. Both IL-1α and IL-1β exert their cellular effects by signalling through IL-1 receptor type 1. A variety of cells such as macrophages, epithelial cells, fibroblasts, keratinocytes, monocytes and dendritic cells secrete IL-1α. Both IL-1α and IL-1β are important in acquired immunity, inflammation, response to infection and production of matrix metalloproteinases (MMPs). The effects of IL-1α are mediated by activation of NF-κB, JNK and MAPK pathways that activated the genes in response to infection and inflammation. Overproduction of IL-1α has been implicated in inflammatory disorders like rheumatoid arthritis and periodontitis
Anti-interleukin-1α specifically reacts with mouse IL-1α. It does not react with human IL-1α and IL-1β or mouse IL-1β.
Anti-interleukin-1α specifically reacts with mouse IL-1α. It does not react with human IL-1α and IL-1β or mouse IL-1β.
Especificidad
The antibody will neutralize the biological activity of recombinant mouse IL-1α, but not recombinant human IL-1α, IL-1β or recombinant mouse IL-1β.
Inmunógeno
recombinant mouse IL-1α.
Aplicación
Anti-interleukin 1α antibody is suitable for neutralization reactions and the recommended ND50 is 0.04-0.2 μg/ml. The antibody may be used for immunoblotting at a working concentration of 1-2 μg/ml. It is also suitable for indirect ELISA applications.
Forma física
Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline pH 7.4, with 5% trehalose.
Cláusula de descargo de responsabilidad
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
¿No encuentra el producto adecuado?
Pruebe nuestro Herramienta de selección de productos.
Producto relacionado
Referencia del producto
Descripción
Precios
Código de clase de almacenamiento
11 - Combustible Solids
Clase de riesgo para el agua (WGK)
WGK 1
Punto de inflamabilidad (°F)
Not applicable
Punto de inflamabilidad (°C)
Not applicable
Equipo de protección personal
Eyeshields, Gloves, type N95 (US)
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Interleukin-1 (IL-1) pathway
Weber A et al
Science Signaling, 3, p-p (2010)
Eun-Bum Kang et al.
Apoptosis : an international journal on programmed cell death, 18(11), 1332-1347 (2013-08-03)
Alzheimer's disease (AD) is characterized by the deposition of aggregated amyloid-beta (Aβ), which triggers a cellular stress response called the unfolded protein response (UPR). The UPR signaling pathway is a cellular defense system for dealing with the accumulation of misfolded
S Z Ben-Sasson et al.
Cytokine, 56(1), 122-125 (2011-08-17)
IL-1 strikingly enhances antigen-driven responses of CD4 and CD8 T cells. It is substantially more effective than LPS and when added to a priming regime of antigen plus LPS, it strikingly enhances cell expansion. The effect is mediated by direct
Charles A Dinarello
Current opinion in pharmacology, 4(4), 378-385 (2004-07-15)
All biological agents currently used for reducing TNFalpha activity in disease are neutralization strategies; however, there are several strategies for reducing interleukin (IL)-1 activities: the IL-1 receptor antagonist (IL-1Ra), anti-IL-1beta monoclonal antibodies, the IL-1 Trap, IL-1 receptor type I antibodies
Emmanuel Contassot et al.
Swiss medical weekly, 142, w13590-w13590 (2012-06-02)
Interleukin 1, one of the first cytokines discovered in the 1980s, and a potent mediator of fever, pain and inflammation, is at present experiencing a revival in biology and medicine. Whereas the mechanism of activation and secretion of interleukin 1β
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico